Loading...
BYSI logo

BeyondSpring Inc.NasdaqCM:BYSI Stock Report

Market Cap US$69.1m
Share Price
US$1.68
My Fair Value
n/a
1Y3.1%
7D7.0%
1D
Portfolio Value
​
View

BeyondSpring Inc.

NasdaqCM:BYSI Stock Report

Market Cap: US$69.1m

BeyondSpring (BYSI) Stock Overview

A clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. More details

BYSI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Earnings have grown 46.6% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($69M)


BYSI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

BeyondSpring Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BeyondSpring
Historical stock prices
Current Share PriceUS$1.68
52 Week HighUS$3.44
52 Week LowUS$1.18
Beta0.41
1 Month Change12.75%
3 Month Change8.39%
1 Year Change3.07%
3 Year Change22.63%
5 Year Change-86.14%
Change since IPO-90.00%

Recent News & Updates

Analysis Article • Apr 28

Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Recent updates

Analysis Article • Apr 28

Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Sep 24

We Think BeyondSpring (NASDAQ:BYSI) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 10

Here's Why BeyondSpring (NASDAQ:BYSI) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 21

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 03

BeyondSpring, Beyond Salvage

BYSI was handed a CRL last year. NSCLC data has also been called into question. The future looks bleak.
Seeking Alpha • Nov 16

Circling Back On BeyondSpring

Today, we look back in on a small oncology company called BeyondSpring for the first time since early this year. The stock quadrupled in August on good trial results but has fallen back 40% since then on some doubts around the data. Temporary setback or beginning of a larger move down? A full investment analysis is provided in the paragraphs below.
Seeking Alpha • Sep 18

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring Pharmaceuticals has the potential to address the billion-dollar anti-cancer markets on top of a large unmet medical need to reduce chemo-induced neutropenia (CIN) with revenues beginning in early 2022. On Monday morning 9/20/21, BeyondSpring will present at ESMO late breaking Phase 3 trial data on Plinabulin to potentially extend survival for Non-Small Cell Lung Cancer (NSCLC) patients. Importantly, FDA approval for CIN by the 11/30/21 PDUFA date will trigger early 2022 commercial launch in the U.S. and give investors greater confidence of FDA approval for NSCLC despite somewhat controversial trial designs. Regulatory approvals for Plinabulin for CIN and NSCLC in both the US and China contribute to our estimated revenues of $127, $330 and $638 million in 2022, 2023 and 2024 and EPS of $4/share and a target price of $120/share by 2024. Further upside potential from Triple I/O Phase 2 data in Small Cell Lung Cancer (SCLC) in 2022, 7-cancer basket trial Phase 1 data in 2022 and SEED Therapeutics protein degradation.
Seeking Alpha • Sep 07

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Recently announced Phase 3 lung cancer data is likely weaker than claimed given the lack of standard disclosure and a history of poor trial conduct. We identify inaccurate data reporting and contradictory management statements regarding critical trial issues. Both strongly suggest BYSI is incapable of producing an adequate NDA. BeyondSpring’s chemotherapy-induced neutropenia US NDA is based on a Phase 3 trial that only enrolled in China and Ukraine. We find it hard to believe such data will satisfy FDA. Two leading oncologists express skepticism regarding Plinabulin’s data and approvability in neutropenia and lung cancer. Base case: Lung cancer data is less than claimed and FDA denial in neutropenia. Shares are worth $5/share (cash plus protein degrader platform value).
Seeking Alpha • Aug 01

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

BYSI has a November PDUFA for plinabulin in chemo-induced neutropenia. There are certain ways in which plinabulin and Spectrum's rolontis complement each other. Below is an overview of plinabulin and a comparison.
Analysis Article • Dec 22

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

A look at the shareholders of BeyondSpring Inc. ( NASDAQ:BYSI ) can tell us which group is most powerful. Institutions...

Shareholder Returns

BYSIUS BiotechsUS Market
7D7.0%1.2%1.6%
1Y3.1%35.1%28.2%

Return vs Industry: BYSI underperformed the US Biotechs industry which returned 35.1% over the past year.

Return vs Market: BYSI underperformed the US Market which returned 28.2% over the past year.

Price Volatility

Is BYSI's price volatile compared to industry and market?
BYSI volatility
BYSI Average Weekly Movement10.8%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BYSI has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BYSI's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201044Lan Huangbeyondspringpharma.com

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN).

BeyondSpring Inc. Fundamentals Summary

How do BeyondSpring's earnings and revenue compare to its market cap?
BYSI fundamental statistics
Market capUS$69.08m
Earnings (TTM)-US$8.18m
Revenue (TTM)n/a
0.0x
P/S Ratio
-8.4x
P/E Ratio

Is BYSI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BYSI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$8.18m
Earnings-US$8.18m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.20
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BYSI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/01 07:53
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BeyondSpring Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Jason Matthew GerberryBofA Global Research
Joshua SchimmerEvercore ISI